664 related articles for article (PubMed ID: 12637461)
61. Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
Jakesz R; Hausmaninger H; Haider K; Kubista E; Samonigg H; Gnant M; Manfreda D; Tschurtschenthaler G; Kolb R; Stierer M; Fridrik M; Mlineritsch B; Steindorfer P; Mittlböck M; Steger G
J Clin Oncol; 1999 Jun; 17(6):1701-9. PubMed ID: 10561206
[TBL] [Abstract][Full Text] [Related]
62. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Cuzick J; Sestak I; Cella D; Fallowfield L;
Lancet Oncol; 2008 Dec; 9(12):1143-8. PubMed ID: 18976959
[TBL] [Abstract][Full Text] [Related]
63. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
[TBL] [Abstract][Full Text] [Related]
64. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group.
Delozier T; Spielmann M; Macé-Lesec'h J; Janvier M; Hill C; Asselain B; Julien JP; Weber B; Mauriac L; Petit JC; Kerbrat P; Malhaire JP; Vennin P; Leduc B; Namer M
J Clin Oncol; 2000 Oct; 18(20):3507-12. PubMed ID: 11032592
[TBL] [Abstract][Full Text] [Related]
65. Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years.
Wu CE; Chen SC; Chang HK; Lo YF; Hsueh S; Lin YC
J Formos Med Assoc; 2016 Apr; 115(4):249-56. PubMed ID: 25900861
[TBL] [Abstract][Full Text] [Related]
66. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
Esteva FJ; Glaspy J; Baidas S; Laufman L; Hutchins L; Dickler M; Tripathy D; Cohen R; DeMichele A; Yocum RC; Osborne CK; Hayes DF; Hortobagyi GN; Winer E; Demetri GD
J Clin Oncol; 2003 Mar; 21(6):999-1006. PubMed ID: 12637463
[TBL] [Abstract][Full Text] [Related]
67. More treatment options for women with hormone receptor-positive breast cancer: guideline update, studies lead to advances in care.
Printz C
Cancer; 2014 Oct; 120(19):2939-40. PubMed ID: 25241884
[No Abstract] [Full Text] [Related]
68. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
Derks MGM; Blok EJ; Seynaeve C; Nortier JWR; Kranenbarg EM; Liefers GJ; Putter H; Kroep JR; Rea D; Hasenburg A; Markopoulos C; Paridaens R; Smeets JBE; Dirix LY; van de Velde CJH
Lancet Oncol; 2017 Sep; 18(9):1211-1220. PubMed ID: 28732650
[TBL] [Abstract][Full Text] [Related]
69. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA
Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816
[TBL] [Abstract][Full Text] [Related]
70. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.
van de Velde CJ; Rea D; Seynaeve C; Putter H; Hasenburg A; Vannetzel JM; Paridaens R; Markopoulos C; Hozumi Y; Hille ET; Kieback DG; Asmar L; Smeets J; Nortier JW; Hadji P; Bartlett JM; Jones SE
Lancet; 2011 Jan; 377(9762):321-31. PubMed ID: 21247627
[TBL] [Abstract][Full Text] [Related]
71. Adjuvant treatment in node-negative, postmenopausal breast cancer.
Hutchins LF; Arick CL
Cancer Invest; 2001; 19(7):706-22. PubMed ID: 11577812
[No Abstract] [Full Text] [Related]
72. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
Fisher B; Dignam J; Bryant J; DeCillis A; Wickerham DL; Wolmark N; Costantino J; Redmond C; Fisher ER; Bowman DM; Deschênes L; Dimitrov NV; Margolese RG; Robidoux A; Shibata H; Terz J; Paterson AH; Feldman MI; Farrar W; Evans J; Lickley HL
J Natl Cancer Inst; 1996 Nov; 88(21):1529-42. PubMed ID: 8901851
[TBL] [Abstract][Full Text] [Related]
73. Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.
Dignam JJ; Wieand K; Johnson KA; Fisher B; Xu L; Mamounas EP
J Natl Cancer Inst; 2003 Oct; 95(19):1467-76. PubMed ID: 14519753
[TBL] [Abstract][Full Text] [Related]
74. Breast cancer update.
Kuter I
Oncologist; 2000; 5(4):285-92. PubMed ID: 10964995
[TBL] [Abstract][Full Text] [Related]
75. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer.
Pyrhönen S; Ellmén J; Vuorinen J; Gershanovich M; Tominaga T; Kaufmann M; Hayes DF
Breast Cancer Res Treat; 1999 Jul; 56(2):133-43. PubMed ID: 10573106
[TBL] [Abstract][Full Text] [Related]
76. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
[TBL] [Abstract][Full Text] [Related]
77. PTEN protein expression in postmenopausal steroid receptor positive early breast cancer patients treated with adjuvant tamoxifen.
Milovanovic Z; Dzodic R; Susnjar S; Plesinac-Karapandzic V; Juranic Z; Tatic S
J BUON; 2011; 16(1):46-51. PubMed ID: 21674849
[TBL] [Abstract][Full Text] [Related]
78. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer.
Love RR; Duc NB; Allred DC; Binh NC; Dinh NV; Kha NN; Thuan TV; Mohsin SK; Roanh le D; Khang HX; Tran TL; Quy TT; Thuy NV; Thé PN; Cau TT; Tung ND; Huong DT; Quang le M; Hien NN; Thuong L; Shen TZ; Xin Y; Zhang Q; Havighurst TC; Yang YF; Hillner BE; DeMets DL
J Clin Oncol; 2002 May; 20(10):2559-66. PubMed ID: 12011136
[TBL] [Abstract][Full Text] [Related]
79. Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial).
Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Fresney M; Kerbrat P; Veyret C; de Lafontan B; Janvier M; Macé-Lesech J
Ann Oncol; 2000 May; 11(5):515-9. PubMed ID: 10907942
[TBL] [Abstract][Full Text] [Related]
80. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer.
Fowble B; Fein DA; Hanlon AL; Eisenberg BL; Hoffman JP; Sigurdson ER; Daly MB; Goldstein LJ
Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):669-77. PubMed ID: 8690632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
